Arrowhead Pharmaceuticals Inc Total Assets
Arrowhead Pharmaceuticals Inc total assets. Based on the latest financial reports, Arrowhead Pharmaceuticals Inc (ARWR) holds total assets worth $1.39 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Arrowhead Pharmaceuticals Inc (ARWR) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Arrowhead Pharmaceuticals Inc (1997–2025)
Total assets of Arrowhead Pharmaceuticals Inc from 1997 to 2025. This chart illustrates how Arrowhead Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See ARWR stock price for real-time trading data and today's change.
Arrowhead Pharmaceuticals Inc - Asset Composition Analysis
Arrowhead Pharmaceuticals Inc Total Assets Breakdown (September 2025)
Arrowhead Pharmaceuticals Inc total assets breakdown as of September 2025. Arrowhead Pharmaceuticals Inc's total assets of $1.39 Billion consist of 65.5% current assets and 34.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 15.6% |
| Accounts Receivable | $6.82 Million | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $6.86 Million | 0.5% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1997–2025)
This chart illustrates how Arrowhead Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore ARWR working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Arrowhead Pharmaceuticals Inc's current assets represent 65.5% of total assets in 2025, an increase from 31.7% in 1997.
- Cash Position: Cash and equivalents constituted 15.6% of total assets in 2025, up from 1.1% in 1997.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1997.
- Asset Diversification: The largest asset category is intangible assets at 0.5% of total assets.
Arrowhead Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Arrowhead Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Arrowhead Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.86 | 6.74 | 12.90 |
| Quick Ratio | 4.86 | 6.74 | 12.62 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $755.15 Million | $592.30 Million | $298.62 Million |
Arrowhead Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Arrowhead Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 19.25 |
| Latest Market Cap to Assets Ratio | 5.76 |
| Asset Growth Rate (YoY) | 27.3% |
| Total Assets | $1.45 Billion |
| Market Capitalization | $8.35 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Arrowhead Pharmaceuticals Inc's assets at a significant premium (5.76x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Arrowhead Pharmaceuticals Inc's assets grew by 27.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Arrowhead Pharmaceuticals Inc (1997–2025)
The table below shows the annual total assets of Arrowhead Pharmaceuticals Inc from 1997 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | $1.45 Billion | +27.25% |
| 2024-09-30 | $1.14 Billion | +48.89% |
| 2023-09-30 | $765.55 Million | +10.64% |
| 2022-09-30 | $691.94 Million | -2.56% |
| 2021-09-30 | $710.15 Million | +35.91% |
| 2020-09-30 | $522.50 Million | +49.35% |
| 2019-09-30 | $349.85 Million | +213.45% |
| 2018-09-30 | $111.61 Million | +7.29% |
| 2017-09-30 | $104.02 Million | -18.84% |
| 2016-09-30 | $128.18 Million | -3.09% |
| 2015-09-30 | $132.27 Million | -27.65% |
| 2014-09-30 | $182.82 Million | +389.74% |
| 2013-09-30 | $37.33 Million | +125.86% |
| 2012-09-30 | $16.53 Million | +4.02% |
| 2011-09-30 | $15.89 Million | +28.61% |
| 2010-09-30 | $12.35 Million | +60.40% |
| 2009-09-30 | $7.70 Million | -55.36% |
| 2008-09-30 | $17.26 Million | -42.20% |
| 2007-09-30 | $29.85 Million | -13.53% |
| 2006-09-30 | $34.53 Million | +18.89% |
| 2005-09-30 | $29.04 Million | +143.72% |
| 2004-09-30 | $11.92 Million | +686.03% |
| 2003-09-30 | $1.52 Million | +2285.01% |
| 2002-09-30 | $63.56K | +37.27% |
| 2001-09-30 | $46.30K | -28.92% |
| 2000-09-30 | $65.15K | -20.83% |
| 1999-09-30 | $82.29K | -2.94% |
| 1998-09-30 | $84.78K | -21.26% |
| 1997-09-30 | $107.68K | -- |
About Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, a… Read more